TITLE:
ADE as Induction Therapy Results in Treatment of Children with Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries
AUTHORS:
Marta Zapata-Tarrés, Rocío Cárdenas-Cardós, Liliana Velasco-Hidalgo, Martín Pérez-García, Alberto Olaya-Vargas, Daniela Cárdenas-Pedraza, Roberto Rivera-Luna
KEYWORDS:
Acute Myeloid Leukemia, Children, Treatment, ADE
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.3,
March
18,
2016
ABSTRACT: Background: In Mexico, AML survival is referred in 30%. Our aim was to
evaluate results with ADE protocol as induction treatment in children with
non-M3 AML in a public Mexican institution. Method: We included patients with
AML in a single institution between 2005 and 2013. All non-M3-AML patients
received ADE as induction therapy (cytarabine 100 mg/m2 in continuous
infusion from day 1 to 7, daunorrubicin 30 mg/m2 days 1, 3, 5 and
etoposide 100 mg/m2 over days 1 to 5). Patients received antibiotic
prophylaxis and strict scheduled appointments to assure adherence and prevent
avoidable emergencies. Main Results: Eighteen patients were included. Median
age was 106 months. One patient died at diagnosis so 17 were eligible for
induction results analysis; eleven needed two cycles and six patients three.
Remission rate was 100%. Analyzing non-M3 patients overall survival was 80.2%
at 100 months. No fatal complications were observed. Stratifying by number of cycles
we observe that patients receiving one ADE cycle had a 0% overall survival at
short follow up, with 2 ADE cycles 80% at 100 months and with 3 cycles 100% at
60 months. Conclusion: ADE induction therapy showed improved results in overall
survival compared with other standard regimens. Following the protocol we
obtained 100% remission. This is an important achievement in our population.
Our focus must be to ameliorate maintenance final results. These results should
be reproduced in other hospitals in Mexico and other countries.